Synphilin-1转基因小鼠模型的制备及帕金森病相关蛋白的表达

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (2937 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the pathogenesis correlafion of Synphilin-1 with Parkinson’s disease. Methods: Generated transgenic mice expressing human Synphilin-1 under the prion protein prom-oter. The genotype of offspring mice was determined by a PCR assay of DNA obtained from tail biopsies.The human Synphilin-1 gene was injected into the fertilized ovum using prion promoter vector to generate the transgenic mice, then PD-related protein immunoblot analysis, the brain tissue slice analysis with immunohistochemistry, double labeling immunofluorescence staining and the phenotypic and athletic analysis of transgenic mice were performed. Results: Synphilin-1 was widely expressed in neurons in the brain, including the substantianigra, but massive loss of dopamine neurons was not observed. In the transgenic mouse brain, Synphilin-1 protein was polyubiquitinated and partially insoluble. Although modified-SHIRPA revealed no significant difference in behavior and morphology, the reduced rotarod performance and step length were observed in transgenic mice as compared with non-transgenic littermates. Conclusion: Synphilin-1 may be involved in motor function, and its accumulation in the central nervous system can cause motor impairments. Synphilin-1 may be involved in regulation of motor function, but had no significant effect of the expression of Parkinson’s disease related proteins nor dopamine neurons in the brain tissue.

Key words： Synphilin-1 Parkinson’s disease transgenic mice tyrosine hydroxylase;α-Synuclein

Received: 14 January 2015

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIN Hongguo
	TANG Weiguo
	JIN Meiyu
	HE Songbin
	ZHOU Min
	Kou Xuelian

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I9/660

[1] Engelender S, Kaminsky Z, Gu X, et al. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions[J]. Nat Genet, 1999, 22(1): 110-114.
[2] Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson’s disease[J]. Ann Neurol, 2000, 47(4): 521-523.
[3] Szargel R, Rott R, Engelender S. Synphilin-1 isoforms in Parkinson’s disease: regulation by phosphorylation and ubiquitylation[J]. Cell Mol Life Sci, 2008, 65(1): 80-88.
[4] Szargel R, Rott R, Eyal A, et al. Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates alpha-synuclein monoubiquitylation and inclusion formation[J]. J Biol Chem, 2009, 284(17): 11706-11716.
[5] Sutachan JJ, Casas Z, Albarracin SL, et al. Cellular and molecular mechanisms of antioxidants in Parkinson’s disease[J]. Nutr Neurosci, 2012, 15(3): 120-126.
[6] Tanji K, Mori F, Kito K, et al. Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease[J]. J Neuropathol Exp Neurol, 2011,70(10): 879-889.
[7] Marx FP, Soehn AS, Berg D, et al. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson’s disease[J]. FASEB J, 2007, 21(8): 1759-1767.
[8] Hoshino T, Kawase Y, Okamoto M, et al. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function[J]. J Immunol, 2001, 166(12): 7014-7018.
[9] Fukuba H, Takahashi T, Jin HG, et al. Abundance of aspargynyl-hydroxylase FIH is regulated by Siah-1 under normoxic conditions[J]. Neurosci Lett, 2008, 433(3): 209-214.
[10] Masuya H, Inoue M, Wada Y, et al. Implementation of the modified-SHIRPA protocol for screening of dominant phenotypes in a large-scale ENU mutagenesis program[J]. Mamm Genome, 2005, 16(11): 829-837.
[11] Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons[J]. J Biol Chem, 2003, 278(44): 43628-43635.
[12] Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders[J]. Science,
2000, 287(5456): 1265-1269.
[13] Antony PM, Diederich NJ, Balling R. Parkinson’s disease mouse models in translational research[J]. Mamm Genome,2011, 22(7-8): 401-419.
[14] Yamashita H, Matsumoto M. Molecular pathogenesis, experimental models, and new therapeutic strategies for Parkinson’s disease[J]. Regen Med, 2007, 2(4): 447-455.
[15] 周辉, 盛汉松, 张弩, 等. 体外诱导分化的多能成体祖细胞移植到帕金森病大鼠模型后的形态学观察[J]. 温州医学院学报, 2011, 41(5): 431-435.
[16] Koppula S, Kumar H, More SV, et al. Recent updates in redox regulation and free radical scavenging effects by herbal products in experimentalmodels of Parkinson’s disease[J].Molecules, 2012, 17(10): 11391-11420.